SCHEDULE: Outlook Therapeutics: Great Point Partners Amends Stake
Beneficial Ownership Amendment
Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, filed an amendment to their Schedule 13G, disclosing a continued beneficial ownership of 4.99% in Outlook Therapeutics, Inc.
Summary
- Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl collectively reported beneficial ownership of 2,220,000 shares of Outlook Therapeutics, Inc. Common Stock.
- This represents 4.99% of the company's outstanding Common Stock.
- The reported shares are primarily derived from warrants to purchase 2,220,000 shares, which are subject to a beneficial ownership cap of 9.99%.
- The calculation of the percentage is based on 42,192,728 shares outstanding as of May 23, 2025, plus the 2,220,000 shares issuable upon warrant exercise.
- The reporting persons share both voting and dispositive power over these shares.
Sentiment
Score: 5
Explanation: The filing is a standard Schedule 13G amendment disclosing beneficial ownership, which is a factual and routine regulatory update. It does not contain new financial performance data, strategic announcements, or significant changes in ownership that would typically alter sentiment.
Positives
- NA
Negatives
- NA
Risks
- The warrants held by the reporting persons are subject to a Beneficial Ownership Cap, restricting their exercise if it would result in beneficial ownership exceeding 9.99% of the outstanding Common Stock.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have entered into a Joint Filing Agreement to file this statement jointly.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake in the company.
Key Dates
| Date | Description |
|---|---|
| 05/23/2025 | Date of Issuer's Prospectus Form 424(b)(5) filing, reporting 42,192,728 shares outstanding. |
| 06/30/2025 | Date of Event Which Requires Filing of this Statement. |
| 08/14/2025 | Date of Joint Filing Agreement and filing date of this Schedule 13G Amendment. |
Keywords
Outlook Therapeutics, OTLK, Great Point Partners, Jeffrey R. Jay, Lillian Nordahl, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.